Farallon Capital Management LLC Makes New Investment in Assembly Biosciences, Inc. $ASMB

Farallon Capital Management LLC bought a new stake in shares of Assembly Biosciences, Inc. (NASDAQ:ASMB) during the 3rd quarter, HoldingsChannel.com reports. The firm bought 1,227,590 shares of the biopharmaceutical company’s stock, valued at approximately $31,426,000. Farallon Capital Management LLC owned 0.16% of Assembly Biosciences at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also modified their holdings of the business. Commodore Capital LP purchased a new position in shares of Assembly Biosciences during the third quarter valued at $25,600,000. Vanguard Group Inc. lifted its stake in Assembly Biosciences by 97.8% in the 3rd quarter. Vanguard Group Inc. now owns 502,112 shares of the biopharmaceutical company’s stock worth $12,854,000 after acquiring an additional 248,287 shares in the last quarter. Patient Square Capital LP purchased a new stake in Assembly Biosciences in the 3rd quarter worth about $3,461,000. Schonfeld Strategic Advisors LLC acquired a new stake in Assembly Biosciences during the 3rd quarter worth about $3,120,000. Finally, Ellsworth Advisors LLC purchased a new position in Assembly Biosciences during the 3rd quarter valued at about $852,000. Institutional investors and hedge funds own 19.92% of the company’s stock.

Assembly Biosciences Stock Performance

Shares of ASMB opened at $28.11 on Monday. The firm has a market cap of $444.70 million, a PE ratio of -5.87 and a beta of 1.11. The firm’s 50 day moving average price is $28.50 and its 200 day moving average price is $29.53. Assembly Biosciences, Inc. has a twelve month low of $7.75 and a twelve month high of $39.71.

Wall Street Analyst Weigh In

A number of equities analysts have recently weighed in on ASMB shares. HC Wainwright reiterated a “buy” rating and issued a $50.00 target price on shares of Assembly Biosciences in a report on Monday, December 22nd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Assembly Biosciences in a research report on Wednesday, January 21st. Finally, Mizuho set a $40.00 price objective on shares of Assembly Biosciences and gave the company an “outperform” rating in a research note on Thursday, November 20th. Five research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Assembly Biosciences currently has a consensus rating of “Moderate Buy” and an average price target of $41.75.

About Assembly Biosciences

Assembly Biosciences, Inc (NASDAQ: ASMB) is a clinical-stage biotechnology company dedicated to the discovery, development and commercialization of novel therapies for hepatitis B virus (HBV) and hepatitis D virus (HDV) infections. The company’s core expertise lies in small-molecule modulation of viral proteins and host-targeted pathways to achieve sustained viral suppression and potential functional cure. Assembly’s research model integrates medicinal chemistry, structural biology and translational virology to advance its pipeline from early discovery through clinical development.

The company’s lead programs include core protein allosteric modulators (CpAMs) designed to disrupt the HBV lifecycle by interfering with capsid assembly and viral DNA replication, as well as prenylation inhibitors targeting the HDV lifecycle.